The proteasome inhibitor, bortezomib, has been shown to possess promising anti-tumor activity and significant efficacy against a variety of malignancies. Different studies demonstrated that bortezomib breaks the chemoresistance in different tumor cells basically by altering nuclear factor-κB (NF-κB) activity. NF-κB has been shown to be constitutively active in the vast majority of primary Hodgkin-Reed-Sternberg (H-RS) cells in lymph node sections and in Hodgkin's lymphoma (HL) cell lines and was suggested to be a central molecular switch in apoptosis resistance in HL. Here we report a bimodal effect of bortezomib in HL cells. Whereas high-dose bortezomib induced direct cytotoxicity which correlated with decreased NF-κB activity, low-dose bortezomib sensitized HL cells against a variety of cytotoxic drugs without altering NF-κB action.
Introduction
The proteasome, a large multicatalytic proteinase complex, is responsible for the degradation of the majority of intracellular proteins. The proteasome has a central role in catabolism of a wide variety of proteins controlling cellular division, growth, function and death. Numerous examples of regulatory proteins including cyclins, cyclin-dependent kinases and kinase inhibitors, oncogenes, tumor suppressor genes, and transcriptional activators and inhibitors have been found to undergo proteasomal proteolysis. Inhibition of the proteasome induces the accumulation of important regulatory intracellular proteins like cytoplasmic inhibitor of NF-κB (IκBα), p53 tumor suppressor gene, p21 and p27 cyclin-dependent kinase inhibitors, which leads to decreased NF-κB activity, increased p53-mediated transcription of genes involved in apoptosis and dysregulation of the cell cycle. [1] [2] [3] [4] In cancer cells, the proteasome is essential to mechanisms underlying tumor cell growth, apoptosis, angiogenesis and metastasis, thereby representing a novel target for cancer therapy. [3] [4] [5] Pharmacologic inhibitors of the proteasome have been shown to possess antitumor activity and have significant efficacy against a variety of malignancies. [1] [2] The best characterized proteasome inhibitor, bortezomib (VELCADE ®, previously known as PS-341; Millennium Pharmaceuticals, Inc.), is a dipeptidyl boronic acid that reversibly inhibits the chymotrypsin-like activity of the proteasome. This agent displays remarkable selectivity toward the proteasome relative to serine and cysteine proteases, and it possesses unique antitumor properties as shown in a National Cancer Institute (NCI)
tumor cell line screen and in several murine xenograft models. [6] [7] [8] [9] [10] [11] Bortezomib is the first proteasome inhibitor that was clinically tested in patients and became a therapeutic modality for multiple myeloma.
Hodgkin lymphoma (HL) accounts for approximately 30% of all malignant lymphomas 12 with the common feature that neoplastic cells constitute only a small minority of the cells in the affected tissue, often corresponding to less than 2% of the total tumor load.
Classical HL (cHL), representing approximately 95% of all HLs, is a fatal disease with 90% of untreated patients dying within 2 to 3 years. 12 The tumor cells of cHL, designated
H-RS cells are mainly derived from germinal center or post-germinal center B-cells, while a very small minority (< 2%) is derived from T-cells. H-RS cells lack specific
For personal use only. on August 16, 2017 . by guest www.bloodjournal.org From functional markers of mature B-or T-cells, seem to be arrested in maturation and therefore should be physiologically prone to undergo apoptosis. [13] [14] The mechanisms of apoptotic resistance in H-RS cells have been intensively investigated during the last decade. It has been shown that H-RS cells are resistant to CD95-mediated apoptosis 15 due to the constitutive expression of cFLIP. 16 In addition, H-RS cells display a defective mitochondrial apoptotic pathway 17 and uniformly show up-regulated XIAP expression 18 which together cause robust resistance to apoptosis.
In this study we investigated the molecular mechanisms of bortezomib action in apoptosis resistant HL B-cell lines. Whereas high-dose bortezomib induced direct cytotoxicity associated with decreased NF-κB activity, low-dose bortezomib generated sensitization without altering NF-κB action in HL cells. Among different cellular targets of bortezomib, XIAP was markedly down-regulated independently of the NF-κB status and any other transcriptional regulations. Similarly, RNAi-mediated XIAP down-regulation generated susceptibility to cytostatic agents suggesting XIAP as the key mediator of chemoresistance in HL cells.
Materials and Methods

Cell lines and cell culture
The establishment and culturing of the HL and control cell lines have been previously described. [15] [16] [17] [18] L591, L428, L1309 and Jurkat cell lines were cultured in VLE RPMI 1640 supplemented with 10% FCS, 2 mM L-glutamine, 100 µg/ml streptomycin and 100 U/ml penicillin (Biochrom, Berlin, Germany 
Sample preparation and immunoblotting
Whole cell extracts were prepared by lysing cells in CHAPS lysis buffer (10 mM HEPES, pH 7.4, 150 mM NaCl, 1% CHAPS, protease complete cocktail) on ice for 20 min. [17] [18] Samples were centrifuged and supernatants were recovered. PARP (Poly (ADP-ribose) Polymerase) cleavage was assessed after incubation of pellets in urea extraction buffer (50 mM Tris pH 6.8, 6 M urea, 3% SDS, 10% glycerol, 0.00125% bromophenol blue, 5%
2-mercaptoethanol) denatured at 100°C for 10 min.
Equal amounts of protein were separated by SDS-PAGE. Rabbit polyclonal antiserum specific for human caspase-9 and Bax, and mouse monoclonal antibodies specific for XIAP, Bcl2, PARP, and cytochrome c were obtained from BD-laboratories (Heidelberg, Germany To silence XIAP expression, pENTR construct was generated with a pair of oligonucleotides derived from XIAP mRNA (the sequence was obtained from Ambion, ID: 2733, Ambion Europe, Huntingdon, U.K.) which includes the unique N-19 target as described in pSUPER RNAi system manual (OligoEngine). 20 The vector uses the polymerase-III H1-RNA gene promoter. After generating an entry clone, the pLenti6/V5DEST XIAP-siRNA expressing vector was created using LR recombination.
The viral particles were produced according to the instructions of the manufactures (ViraPower Lentiviral expression system, Invitrogen, Karlsruhe, Germany). The recombinant lentiviral constructs were transduced into the cells and stable cell lines were generated by blasticidin (Invitrogen, Karlsruhe, Germany) selection.
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Results
Bortezomib-induced direct cytotoxicty is associated with decreased NF-κB activity in HL B-cell lines.
Several Similarly, both bortezomib and Bay exerted cytotoxic effects in a dose-dependent manner suggesting an anti-proliferating activity of high-dose bortezomib correlating with reduction of NF-κB activity (Fig. 1D ).
Sensitization of HL B-cells against cytostatic agents without NF-κB inhibitory action
Different studies demonstrated that bortezomib potentiates the activity of other chemotherapeutics, in part by down-regulating chemoresistance pathways. 1D ) or NF-κB inhibitory activity (Fig. 1B-C) significantly enhanced the potency of cytotoxic agents (up to 50% more cytotoxicity) ( Fig. 2A) which was accompanied by cleavage of PARP as a sign of ongoing apoptosis in HL B-cells (Fig. 2B ). These data suggest that bortezomib breaks the chemoresistance phenotype of HL B-cells by targeting molecular mechanisms other than NF-κB.
Bortezomib induced XIAP down-regulation without NF-κB inhibition
In various tumor cell types bortezomib has been described to overcome the antiapoptotic program by altering the expression levels of different modulators of apoptosis including Bcl-2, Bax, Mcl1, and inhibitor of apoptosis proteins (IAPs). The specificity of XIAP knock-down was revealed by unaltered expression of caspase-3, Smac, cIAP1, cIAP2 and actin (Fig. 4A) .
We finally examined whether XIAP down-regulation results in increased susceptibility to cytotoxic drugs by analyzing cell viability and PARP cleavage. As shown in Fig. 4C -D, cytotoxic agents induced significantly increased cell death of L428-XIAP-shRNA and L591-XIAP-shRNA and PARP cleavage. As already shown in Fig. 2A , parental L428 and L591 or derivatives expressing scrambled shRNA where only partially affected and did not show any PARP cleavage. Apparently, selective down-regulation of XIAP recapitulates the chemosensitivity phenotype of bortezomib.
Discussion
In this study, we scrutinized bortezomib as an anti-proliferative agent in Hodgkin lymphoma B-cell lines. We describe here a bimodal action of bortezomib where highdose bortezomib induces direct cytotoxicity and inhibition of NF-κB activity. At lower doses bortezomib was neither cytotoxic nor did it alter NF-κB activity yet established a marked sensitization against a variety of cytotoxic drugs. A major observation of this study is that bortezomib selectively and independent of NF-κB down-regulates XIAP, previously shown to be a key mediator of apoptosis resistance in HL cells.
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Proteasome inhibitors first drew clinical interest as potential anti-neoplastic agents owing to their ability to inhibit NF-κB activity. 
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